Department of Nutrition and Health, China Agricultural University, Beijing 100091, China.
School of Food and Chemical Engineering, Beijing Technology and Business University, Beijing 100048, China.
Nutrients. 2021 Jun 29;13(7):2238. doi: 10.3390/nu13072238.
Probiotics have been shown to benefit patients with constipation and depression, but whether they specifically alleviate constipation in patients with depression remains unclear. The aim of this study was to investigate the effect of strain Shirota (LcS), formerly strain Shirota, on constipation in patients with depression with specific etiology and gut microbiota and on depressive regimens. Eighty-two patients with constipation were recruited. The subjects consumed 100 mL of a LcS beverage (10 CFU/mL) or placebo every day for 9 weeks. After ingesting beverages for this period, we observed no significant differences in the total patient constipation-symptom (PAC-SYM) scores in the LcS group when compared with the placebo group. However, symptoms/scores in item 7 (rectal tearing or bleeding after a bowel movement) and items 8-12 (stool symptom subscale) were more alleviated in the LcS group than in the placebo group. The Beck Depression Index (BDI) and Hamilton Depression Rating Scale (HAMD) scores were all significantly decreased, and the degree of depression was significantly improved in both the placebo and LcS groups ( < 0.05), but there was no significant difference between the groups. The LcS intervention increased the beneficial , and levels and decreased the bacterial levels related to mental illness, such as , and Additionally, the interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) levels were significantly decreased in both the placebo and LcS groups ( < 0.05). In particular, the IL-6 levels were significantly lower in the LcS group than the placebo group after the ingestion period ( < 0.05). In conclusion, the daily consumption of LcS for 9 weeks appeared to relieve constipation and improve the potentially depressive symptoms in patients with depression and significantly decrease the IL-6 levels. In addition, the LcS supplementation also appeared to regulate the intestinal microbiota related to mental illness.
益生菌已被证明对便秘和抑郁症患者有益，但它们是否能专门缓解抑郁症患者的便秘仍不清楚。本研究旨在调查先前的 Shirota 株（LcS）对具有特定病因和肠道微生物群的抑郁症伴便秘患者的便秘及抑郁方案的影响。招募了 82 名便秘患者。受试者每天饮用 100 mL LcS 饮料（10 CFU/mL）或安慰剂，持续 9 周。在饮用饮料期间，与安慰剂组相比，LcS 组患者的总便秘症状评分（PAC-SYM）无显著差异。然而，LcS 组在第 7 项（排便后直肠撕裂或出血）和第 8-12 项（粪便症状子量表）症状/评分方面的改善比安慰剂组更为明显。贝克抑郁指数（BDI）和汉密尔顿抑郁评定量表（HAMD）评分均显著降低，安慰剂和 LcS 组的抑郁程度均显著改善（<0.05），但两组间无显著差异。LcS 干预增加了有益的 和 水平，降低了与精神疾病相关的细菌水平，如 、 和 。此外，安慰剂和 LcS 组的白细胞介素（IL）-1β、IL-6 和肿瘤坏死因子-α（TNF-α）水平均显著降低（<0.05）。特别是在摄入期后，LcS 组的 IL-6 水平明显低于安慰剂组（<0.05）。总之，连续 9 周每天饮用 LcS 似乎可以缓解便秘并改善抑郁症患者的潜在抑郁症状，并显著降低 IL-6 水平。此外，LcS 补充剂似乎也可以调节与精神疾病相关的肠道微生物群。
